ES2731725T3 - Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada - Google Patents

Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada Download PDF

Info

Publication number
ES2731725T3
ES2731725T3 ES13802833T ES13802833T ES2731725T3 ES 2731725 T3 ES2731725 T3 ES 2731725T3 ES 13802833 T ES13802833 T ES 13802833T ES 13802833 T ES13802833 T ES 13802833T ES 2731725 T3 ES2731725 T3 ES 2731725T3
Authority
ES
Spain
Prior art keywords
treatment
long
inhibitor
level
tumor marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13802833T
Other languages
English (en)
Spanish (es)
Inventor
Yen Chia
Ute Hoch
Alison Hannah
Michael Eldon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Application granted granted Critical
Publication of ES2731725T3 publication Critical patent/ES2731725T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES13802833T 2012-11-28 2013-11-27 Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada Active ES2731725T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730900P 2012-11-28 2012-11-28
PCT/US2013/072205 WO2014085571A1 (en) 2012-11-28 2013-11-27 Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor

Publications (1)

Publication Number Publication Date
ES2731725T3 true ES2731725T3 (es) 2019-11-18

Family

ID=49753531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13802833T Active ES2731725T3 (es) 2012-11-28 2013-11-27 Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada

Country Status (10)

Country Link
US (2) US10132810B2 (enExample)
EP (1) EP2926137B1 (enExample)
JP (1) JP6284541B2 (enExample)
KR (1) KR102120510B1 (enExample)
CN (1) CN104813167B (enExample)
AU (1) AU2013352223B2 (enExample)
CA (1) CA2890082C (enExample)
ES (1) ES2731725T3 (enExample)
MX (1) MX366911B (enExample)
WO (1) WO2014085571A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191022B (zh) * 2016-02-22 2019-08-20 叶尚勉 一种肿瘤特异抗原及其应用
EP3852793B1 (en) 2018-09-17 2025-11-19 The Children's Hospital Of Philadelphia Macromolecular prodrug peg-[sn22]4
CN112102914A (zh) * 2020-09-25 2020-12-18 复旦大学附属肿瘤医院 曲妥珠单抗生物类似药的评价方法及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
JP5276982B2 (ja) * 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
ES2436109T3 (es) 2006-02-09 2013-12-27 Belrose Pharma Inc. Conjugados poliméricos de múltiples brazos de 7-etil-10-hidroxicamptotecina para el tratamiento del cáncer de mama, del cáncer colorrectal, del cáncer de páncreas, de ovario y de pulmón
WO2009059393A1 (en) * 2007-11-06 2009-05-14 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient sample
MX2011003063A (es) * 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
CA2780645C (en) 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
WO2012031320A1 (en) * 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
JP6138140B2 (ja) 2011-10-25 2017-05-31 ネクター セラピューティクス 癌患者の治療

Also Published As

Publication number Publication date
CN104813167B (zh) 2019-04-09
MX2015006733A (es) 2015-08-14
CN104813167A (zh) 2015-07-29
KR20150089013A (ko) 2015-08-04
JP6284541B2 (ja) 2018-02-28
US20150309032A1 (en) 2015-10-29
EP2926137A1 (en) 2015-10-07
US20190049450A1 (en) 2019-02-14
CA2890082C (en) 2021-07-06
MX366911B (es) 2019-07-30
WO2014085571A1 (en) 2014-06-05
CA2890082A1 (en) 2014-06-05
KR102120510B1 (ko) 2020-06-08
AU2013352223A1 (en) 2015-05-21
JP2016502083A (ja) 2016-01-21
US10132810B2 (en) 2018-11-20
AU2013352223B2 (en) 2019-07-18
EP2926137B1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
US11844795B2 (en) Combination therapy for cancer treatment
ES3009356T3 (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
US20230372499A1 (en) Dendrimer compositions and methods for drug delivery
AU2016287508B2 (en) Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy
Maity et al. Targeting the epidermal growth factor receptor with molecular degraders: state-of-the-art and future opportunities
US20240082436A1 (en) Synergistic cancer treatment
US20170165322A1 (en) Peptide and small molecule agonists of epha and their uses in disease
US20190049450A1 (en) Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor
Lee et al. Pheophorbide A and SN38 conjugated hyaluronan nanoparticles for photodynamic-and cascadic chemotherapy of cancer stem-like ovarian cancer
Xie et al. Preclinical characterization and clinical activity of RNK08954, a highly selective and orally bioavailable KRAS G12D inhibitor
Lian et al. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1
ES2458818T3 (es) Métodos para evaluar la actividad de una composición de polisacárido
TW202600140A (zh) Wee1抑制劑及拓樸異構酶1抑制劑之組合
WO2024061848A1 (en) Novel compositions based on polyinosinic-polycytidylic acid
US10159659B2 (en) Predicting response to cancer therapy
JP6138140B2 (ja) 癌患者の治療
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CN114126656A (zh) 治疗癌症的方法和用途
Makeyev et al. Topoisomerase I inhibitors: current use and prospects
HK1214145A1 (zh) 无副作用的抗癌剂